Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Kasper Lamberth, PhD Principal Scientist, Screening & Bioassay Technology at Novo Nordisk A/S


Kasper Lamberth, Ph.D., is Principal Specialist within the field of in silico and in vitro immunogenicity assessment at Global Research Technologies, Novo Nordisk A/S. Dr. Lamberth joined Novo Nordisk 10 years ago and during this time he has worked with development of immunogenicity prediction tools as well as high throughput screening technologies. Prior to Novo Nordisk A/S, Dr. Lamberth worked for eight years with predictive immunogenicity tools, especially with MHC polymorphism and the identification of T-cell epitopes within the field of infectious diseases at Copenhagen University. Dr. Lamberth holds a MS in Biochemistry and a PhD in Immunology, both from Copenhagen University

Agenda Sessions